Navigation Links
Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose

Trial Convincingly Proves Functionality in Humans of CTI's Programmable, Pulsatile, Passive Transdermal Drug Delivery Device - ChronoDose

BASEL, Switzerland and TRENTON, N.J., May 03, 2007 /PRNewswire/ -- Chrono Therapeutics Inc. (CTI) announced today the successful completion of its first phase human clinical trial of its programmable, pulsatile, passive transdermal drug/device combination product: ChronoDose(TM). CTI intends to publish this clinical data in leading scientific and medical journals by year end.

CLINICAL STUDY DESIGN

The trial was conducted between February and April 2007 at the University Hospital Basel, Switzerland, Division of Clinical Pharmacology and Toxicology. Georgios Imanidis, PhD, of the University of Basel was the Principal Investigator on behalf of CTI.

This study was an open, randomized, three period, single-center, dose- escalation study. Thirty-six independent human transdermal tests were conducted on male volunteers using wristwatch-like ChronoDose(TM) devices. The trial successfully proved the efficacy of the device on human subjects using its model drug compound. The dose escalation trial showed statistically significant modulation and control of the dosing profiles. Using low, medium and high concentrations, for 16 hours, the model drug permeated each subject's skin on multiple occasions, resulting in clear and distinct peaks and troughs of therapeutically effective and well-targeted blood plasma concentration levels. A non-compartmental and compartmental model based analysis of pharmacokinetics will be utilized. Local and systemic tolerability of the model drug after its transdermal administration was better than planned.

Dr. Georgios Imanidis commented, "CTI has for the first time in transdermal drug delivery history successfully completed a significant human trial with a passive, automated and programmable multiple dosing transdermal device syste m. We are extremely pleased with the excellent results".

Guy DiPierro, CEO and President of CTI noted, "This solid and convincing clinical data along with initial human data generated last summer will help us to rapidly commercialize our initial drug product. We are particularly pleased that ChronoDose(TM) produced targeted blood plasma concentrations as accurately as it did and at the intended time periods."

    ABOUT CHRONO THERAPEUTICS INC.

    -- Chrono Therapeutics Inc. (CTI) was founded in late 2003 to become the

       global leader in Chrono-Pharmacologically based prescription and OTC

       drug delivery.

    -- Today CTI is a specialty pharmaceutical company that developing,

       manufacturing and commercializing Chrono-Pharmacologically based drug

       products.

    -- CTI has created and patented the world's first automated and

       programmable, passive transdermal drug delivery device-ChronoDose(TM)

    -- ChronoDose

        -- Dramatically improves therapies

        -- Significantly decreases symptoms and side effects

        -- Ensures less built-up tolerance to the drug

PATIENT NON-COMPLIANCE

Annually, over 20% of hospital admissions result from patient non-compliance, costing the healthcare industry over $100 billion/year. ChronoDose(TM) offers a revolutionary step forward in guaranteed patient compliance, especially for the elderly, hospitalized, or the mentally ill.

    Contact:

    Chrono Therapeutics Inc.

    Guy DiPierro, President and Chief Executive Officer

    Phone: (609) 838 2572

    Email: 

    Website: ChronoDose.com

Info@ChronoDose.com

CONTACT: Guy DiPierro, President and Chief Executive Officer of ChronoTherapeutics Inc., +1-609-838-2572, Info@ChronoDose.com

Web site: http://www.chr onodose.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
9. Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):